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Microvascular Obstruction
Underlying Pathophysiology and Clinical Diagnosis
Sebastiaan C. A. M. Bekkers, MD,* Saami K. Yazdani, PHD,† Renu Virmani, MD,†
Johannes Waltenberger, MD, PHD*
Maastricht, the Netherlands; and Gaithersburg, Maryland
Successful restoration of epicardial coronary artery patency after prolonged occlusion might result in microvas-
cular obstruction (MVO) and is observed both experimentally as well as clinically. In reperfused myocardium,
myocytes appear edematous and swollen from osmotic overload. Endothelial cell changes usually accompany
the alterations seen in myocytes but lag behind myocardial cell injury. Endothelial cells become voluminous,
with large intraluminal endothelial protrusions into the vascular lumen, and together with swollen surrounding
myocytes occlude capillaries. The infiltration and activation of neutrophils and platelets and the deposition of
fibrin also play an important role in reperfusion-induced microvascular damage and obstruction. In addition to
these ischemia-reperfusion-related events, coronary microembolization of atherosclerotic debris after percutane-
ous coronary intervention is responsible for a substantial part of clinically observed MVO. Microvascular flow af-
ter reperfusion is spatially and temporally complex. Regions of hyperemia, impaired vasodilatory flow reserve
and very low flow coexist and these perfusion patterns vary over time as a result of reperfusion injury. The MVO
first appears centrally in the infarct core extending toward the epicardium over time. Accurate detection of MVO
is crucial, because it is independently associated with adverse ventricular remodeling and patient prognosis. Sev-
eral techniques (coronary angiography, myocardial contrast echocardiography, cardiovascular magnetic reso-
nance imaging, electrocardiography) measuring slightly different biological and functional parameters are used
clinically and experimentally. Currently there is no consensus as to how and when MVO should be evaluated af-
ter acute myocardial infarction. (J Am Coll Cardiol 2010;55:1649–60) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.037d
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timely reperfusion in patients with acute myocardial infarc-
ion (AMI) salvages myocardium and reduces mortality (1).
owever, successful restoration of epicardial coronary artery
atency after prolonged occlusion does not always lead to
dequate reperfusion at the microvascular level. This phe-
omenon of no-reflow or microvascular obstruction (MVO)
s observed both experimentally as well as clinically (2,3).
ccurate detection and quantification of MVO is impor-
ant, because previous studies have shown that MVO is
ndependently associated with adverse ventricular remodel-
ng and patient prognosis (2,4–7). The “open epicardial
rtery hypothesis” should thus be shifted downstream to an
open micro-vessel hypothesis” for reflecting optimal reper-
usion (8).
Although both the clinical as well as the experimental
etting of ischemia-reperfusion share important underlying
athophysiologic aspects, the experimental models of coro-
ary occlusion and reperfusion are lacking certain aspects
requently present in the clinical situation. For instance,
rom the *Department of Cardiology, Maastricht University Medical Center,
aastricht, the Netherlands; and the †CVPath Institute, Inc., Gaithersburg, Maryland.w
Manuscript received July 14, 2009; revised manuscript received November 18,
009, accepted December 16, 2009.istal coronary microembolization of atherosclerotic debris
r thrombotic material might be responsible for a substan-
ial part of clinically observed MVO, which is not simulated
n standard animal models of ischemia and reperfusion (6).
Imaging techniques play an important role in the devel-
pment and evaluation of future cardioprotective interven-
ions (9). However, a “gold standard” for the detection of
VO has not been established, and several techniques
easuring slightly different biological parameters are being
sed clinically and experimentally. The sensitivity and spec-
ficity of all these techniques is as yet undetermined. Following
clinical case presentation, we review the underlying patho-
hysiology of myocardial ischemia with an emphasis on MVO
nd review current techniques to detect MVO.
ase Presentation
49-year-old woman with a history of smoking presented
o the emergency department after 3 h of crushing retro-
ternal chest pain. The electrocardiogram (ECG) showed
T-segment elevation in leads V1 to V4, indicating acute
ransmural anteroseptal ischemia (Fig. 1A). She was treated
ith aspirin 300 mg, clopidogrel 600 mg, weight-adjusted
c
c
a
L
1
c
M
c
a
A
(
M
d
M
T
a
a
a
t
f
l
s
g
s
t
N
l
i
c
a
i
i
A
I
I
a
s
p
s
i
o
c
i
o
f
a
“
a
s
m
i
T
n
w
n
d
n
m
m
p
m
m
i
w
a
t
e
1650 Bekkers et al. JACC Vol. 55, No. 16, 2010
Microvascular Obstruction April 20, 2010:1649–60low-molecular weight heparin, ni-
troglycerine, a beta-blocker, and a
glycoprotein IIb/IIIa inhibitor.
Coronary angiography showed
an occlusive thrombus in the mid
left anterior descending artery at
the bifurcation of the second di-
agonal branch (Figs. 2A and 2B).
Subsequently and approximately
4 h after symptom onset, percu-
taneous coronary intervention
(PCI) with thrombosuction and
stenting was performed (Fig.
2C). Despite an angiographically
optimal result without residual
stenosis, antegrade epicardial
flow was only partially restored
to Thrombolysis In Myocardial
Infarction (TIMI) flow grade 2,
even after intracoronary adeno-
sine injection (Fig. 2D).
In the Intensive Cardiac Care
Unit, her chest pain completely
subsided. Despite significant ST-
segment resolution (STR 70%),
persistent ST-segment elevation in
leads V1 to V3 was still present 40
min after PCI (Fig. 1B). The peak
creatine kinase level of 900 U/l was
reached 12 h after admission.
Cardiovascular magnetic reso-
nance imaging (MRI) on day 4
demonstrated antero-septal akine-
sia, a left ventricular (LV) end-
diastolic volume of 149 ml, LV
stroke volume of 67 ml, and ejec-
tion fraction (EF) of 45%. Early
ontrast-enhanced cardiovascular MRI performed 2 min after
ontrast injection showed a central hypointense area in the
nteroseptal wall corresponding to MVO (Fig. 3A, arrows).
ate gadolinium-enhanced cardiovascular MRI (LGE-CMR)
0 min after contrast injection showed an anteroseptal myo-
ardial infarction (Fig. 3B, arrowheads) with a central zone of
VO (Fig. 3B, arrows).
Her hospital course was uneventful, and she was dis-
harged on day 6 with aspirin, clopidogrel, statin,
ngiotensin-converting enzyme inhibitor and beta-blocker.
fter 3 months she was in New York Heart Association
NYHA) functional class III, and a repeat cardiovascular
RI showed an increased LV end-diastolic volume and
ecreased EF (41%).
echanisms of Ischemic Myocardial Injury
he anatomic and biochemical events of ischemic cell injury
Abbreviations
and Acronyms
ATP  adenosine
triphosphate
CTFC  corrected
Thrombolysis In Myocardial
Infarction frame count
EC  endothelial cell
ECG  electrocardiogram/
electrocardiography
EF  ejection fraction
FPP-CMR  first-pass
perfusion cardiovascular
magnetic resonance
imaging
IRA  infarct-related artery
LGE-CMR  late
gadolinium-enhanced
cardiovascular magnetic
resonance imaging
LV  left ventricle/
ventricular
MCE  myocardial contrast
echocardiography
MRI  magnetic resonance
imaging
MVO  microvascular
obstruction
PCI  percutaneous
coronary intervention
STR  ST-segment
resolution
TIMI  Thrombolysis In
Myocardial Infarction
TMP  Thrombolysis In
Myocardial Infarction
myocardial perfusionnd death have been well-described (9,10). Under normal aerobic conditions cardiac energy is acquired from fatty
cids, which supply 60% to 90% of the energy for adenosine
riphosphate (ATP) synthesis. The remaining energy comes
rom oxidation of pyruvate formed from glycolysis and
actate oxidation. Sudden occlusion of a coronary artery
hifts aerobic or mitochondrial metabolism to anaerobic
lycolysis within seconds. Reduced aerobic ATP formation
timulates glycolysis and increases myocardial glucose up-
ake and glycogen breakdown. A decrease in ATP inhibits
a/K-ATPase, increasing intracellular Na and Cl,
eading to cell swelling. Derangements in transport systems
n the sarcolemma and sarcoplasmic reticulum increase
ytosolic Ca2, inducing activation of proteases and alter-
tions in contractile proteins. Pyruvate is not readily oxidized
n the mitochondria, leading to production of lactate, fall in
ntracellular pH, reduction in contractile function, and greater
TP requirement to maintain Ca2 hemostasis (11).
nfarct Region and Reperfusion
nfarct size is directly related to the duration of coronary
rtery occlusion. In animal models, coronary artery occlu-
ion of 15 to 20 min followed by reperfusion completely
revents myocardial cell necrosis, whereas 40 min of occlu-
ion results in focal or diffuse subendocardial necrosis
nvolving 28  5% of the coronary bed at risk (12). At 3 h
f occlusion, myocardial necrosis involves 70  5% of the
oronary bed, and an additional 3 h results in an increase of
nfarct size to 72  6%, similar to permanent coronary
cclusion rates (79  3%). To achieve benefit from reper-
usion, as learned in animal models, it is reasonable to
dminister all therapeutic interventions within the 3-h
window.”
In ischemic but reversibly injured myocardium, myocytes
re edematous and swollen from osmotic overload. The cell
ize is increased with decreased glycogen content (3). The
yocyte fibrils are relaxed and thinned; I-bands are prom-
nent secondary to noncontracting ischemic myocytes (13).
he nuclei show mild condensation of chromatin at the
ucleoplasm. The cell membrane (sarcolemma) is intact
ith no breaks. The mitochondria are swollen with loss of
ormal dense mitochondrial granules or granular flocculent
ensities. Irreversible injured myocytes contain shrunken
uclei with marked chromatin margination. The 2 hall-
arks of irreversible injury are cell membrane breaks and
itochondrial presence of small osmophilic densities (3).
Endothelial cell (EC) changes of ischemia usually accom-
any the alterations seen in the myocytes but lag behind
yocardial cell injury (14). In a canine model, EC abnor-
alities are not seen until 60 min. These abnormalities
nclude focal EC swelling with loss of pinocytotic vesicles,
hich are observed in 20% of ECs (14). As ischemia
dvances, the number of affected ECs increases (40% at 90
o 180 min). Moreover, as ischemia prolongs, greater
ndothelial changes result, including clumping and margin-
tion of nuclear chromatin, marked swelling of the cyto-
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April 20, 2010:1649–60 Microvascular Obstructionlasm, formation of intraluminal blebs, and even disruption
f EC borders, hemorrhage, and fibrin deposition (Fig. 4)
14–16). The microvasculature can also be obstructed by
xtravascular compression from myocyte edema. Overall, it
eems that microvascular damage lags behind myocardial
ell injury, ultrastructurally, and is probably not the primary
ause of myocyte injury until reperfusion occurs (14,17).
he “No-Reflow” Phenomenon
r Microvascular Obstruction
balance exists between the benefits of reperfusion to
educe infarct size and reperfusion injury, which depends on
he duration of occlusion. In general, if ischemic myocar-
ium is reperfused early, the degree of myocardial salvage
reatly exceeds damage from free radicals and calcium-
oading caused by reperfusion. These positive functional
onsequences of reperfusion are most beneficial within the
nitial 12 h after occlusion in humans.
Reperfusion injury is defined as reperfusion-related ex-
ansion or worsening of ischemic cardiac injury leading to
ecreased contractility, an increased arrhythmogenic thresh-
ld, conversion of reversible to irreversible myocyte injury,
nd microvascular dysfunction (3). At the time of myocar-
ial reperfusion, there is an abrupt increase in intracellular
a2, leading to a disturbance in the normal mechanisms
hat regulate Ca2 in the cardiomyocyte, known as the
alcium paradox (18). This intracellular Ca2 overload
nduces death by causing hypercontracture of myocytes and
itochondrial permeability transition pore opening (9,18).
Microvascular obstruction in the heart was first described
Figure 1 Electrocardiogram on Admission and After Interventio
(A) The ST-segment elevation in leads V1 to V4 indicating acute transmural ischem
ST-segment elevation, persistent ST-segment elevation in leads V2 to V3 (1 to 2 my Kloner et al. (3) and consists of explosive EC swelling on aeperfusion of an ischemic bed (19). Endothelial protrusion
y cell swelling together with neutrophils, red blood cells,
nd platelets cause capillary obstruction (Fig. 4) (3). Mi-
rovessels ultimately rupture, with fibrin and platelet depo-
ition and red and white blood cell extravasation. Further-
ore, surrounding myocardial cells swell, potentially
ompressing capillaries. These changes in the capillary bed
an result in poor perfusion of the surrounding potentially
iable myocytes with resultant cell death (10,20). The failure
o reperfuse viable, severely ischemic myocytes (reversible
njury) with resultant myocyte cell death (irreversible injury)
t the time of reperfusion (the no-reflow phenomenon) has
een described after 90 min in a canine model (3). Reper-
usion, therefore, as described by Braunwald and Kloner
21) is a “double-edged” sword, because it can result in the
eath of potentially salvageable myocardium.
Neutrophils have also been implicated in causing reper-
usion injury in the myocardium and other organs. Neutro-
hils are activated early during myocardial ischemia and
recede the appearance of histological tissue injury (17).
eperfusion markedly enhances the infiltration of neutro-
hils into the ischemic region (22). The essential initiating
tep involves interaction of neutrophils with vascular ECs
adhesion). This is followed by activation, diapedesis, and
xtravascular migration into surrounding myocytes. Produc-
ion of additional chemoattractants by activated neutrophils
mplifies the initial inflammatory response. Neutrophil
ctivation causes a greatly enhanced oxygen uptake by the
ell, resulting in the production of large quantities of
eactive oxygen species that might lead to disruption of EC
the anterior wall. (B) Despite 70% resolution of initial
still present 40 min after percutaneous coronary intervention.n
ia of
m) isnd inactivate antiproteases present in the plasma (23).
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Microvascular Obstruction April 20, 2010:1649–60In addition to these ischemia-reperfusion-related events,
istal coronary microembolization of atherosclerotic debris
r thrombotic material is responsible for a substantial part of
linically observed MVO (6,24) (Fig. 5). Microemboli are
istopathologically associated with MVO, myocyte necrosis
nd edema, and EC sloughing within the intramyocardial
apillaries (25,26). The rate of coronary microembolization
s highest in documented epicardial coronary thrombosis,
eaching 30% to 54% (27,28) and even higher (79%) in
MI patients (29). Few data compare acute plaque rupture
ersus acute plaque erosion; however, the authors have
oted a higher rate of thrombotic microembolization with
laque erosion. In hearts with acute coronary thrombi,
vidence of distal embolization was more frequent in ero-
ions than ruptures. These thrombi were associated with
ocal myocardial necrosis. Other potential sources of distal
mbolization include primary PCI, PCI of diseased (ath-
rosclerotic) saphenous vein grafts, and thrombolysis. The
eported incidence of distal embolization due to soft friable
therosclerotic plaque and adherent thrombus, after PCI of
Figure 2 Acute Coronary Angiogram
Proximal occlusion of the left anterior descending artery (LAD) (A) (arrow). After in
LAD (arrow) and second diagonal branch (*) can be seen (B). After thrombosuctio
to Thrombolysis In Myocardial Infarction flow grade 2, despite an angiographicallyypass grafts ranges from 2% to 42% (30–32). Angiographic avidence of distal embolization in patients treated with
rimary PCI has been shown to occur in approximately 15%
o 19% (33,34) (Fig. 6).
Microvascular flow within the reperfused bed is both
patially and temporarily complex. Apparently, blood flow
n the area of structural MVO is not completely absent but
ather very low, ranging between 0.13 and 0.37 ml/g/min,
hich is 50% of baseline blood flow (35,36). Microvas-
ular obstruction first appears centrally in the infarct core
xtending toward the epicardium over time. Different myo-
ardial regions can be distinguished (Fig. 7) (37). In the
oninfarcted region, microvasculature is intact and blood
ow is normal. In the noninfarcted (stunned) area-at-risk,
icrovasculature is structurally and functionally still intact. The
nfarcted region has outer zones of intact microvasculature with
o-existing areas of hyperemia, low reflow, and impaired flow
eserve, depending on the degree of capillary damage.
Myocardial blood flow in certain areas of MVO is
yperemic during the first 2 min of reperfusion but progres-
ively decreases within 2 to 3 h after reperfusion, resulting in
tion of the first guidewire, intraluminal thrombus (haziness) at the bifurcation of
stenting followed by kissing balloon inflation (C), flow was only partially restored
l result (D).troduc
n and
optima2-fold increase of MVO (35,38). A further increase in
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April 20, 2010:1649–60 Microvascular ObstructionVO size has been demonstrated up to 48 h after initiation
f reperfusion (39). This progression of MVO is presumably
elated to reperfusion injury. Therefore, therapeutic inter-
entions trying to attenuate MVO are likely to be most
uccessful when initiated early after reperfusion.
iagnosis of MVO
oronary angiography. After the recognition that com-
lete thrombotic coronary occlusion caused AMI and
hat early reperfusion with thrombolytic agents increased
yocardial salvage and reduced mortality, there was a
eed to angiographically assess the quality of reperfusion
40). Successful reperfusion is defined by assessing ante-
rade angiographic epicardial blood flow, graded as TIMI
ow; TIMI flow grade 0: absent antegrade flow; TIMI
ow grade 1: partial contrast penetration beyond an
cclusion with incomplete distal filling; TIMI flow grade
: patent epicardial artery with opacification of the entire
istal artery (however, contrast filling or washout is
elayed); TIMI flow grade 3: patent epicardial artery
ith normal flow.
Early studies using this angiographic assessment found
hat mortality was significantly lower in patients with
IMI flow grade 3 than in those with other TIMI flow
rades (4% vs. 8%, p  0.01), and importantly, TIMI
ow grade 2 was not associated with a significant survival
Figure 3 Cardiovascular MRI
A set of 2 corresponding short-axis images with a single breathhold 3-dimensional
tion) contrast-enhanced cardiovascular magnetic resonance imaging (MRI) showing
anteroseptal region (arrows, early MVO). (B) Late gadolinium-enhanced cardiovasc
anteroseptal myocardial infarction (arrowheads) with a central zone of MVO (arrow
trast penetration over time (see Cardiovascular MRI section).dvantage compared with TIMI flow grades 0 or 1 (41). aTIMI flow grade 2 without a residual obstructive
esion has been generally regarded as the “angiographic
o reflow” (42). Although angiographic assessment of
eperfusion is still useful in daily clinical practice, the
linician should be aware that TIMI flow grade 3 is not
lways synonymous with optimal tissue reperfusion, be-
ause MVO can be demonstrated in a substantial number
f these patients (2).
Because the TIMI flow grading system is semi-
uantitative and subjective, a more objective angiographic
arker of tissue perfusion was developed. The corrected
IMI frame count (CTFC) assesses the number of cine
rames required for contrast to first reach standardized distal
oronary landmarks in the culprit artery. A higher CTFC
nd thus slower epicardial flow 90 min after administration
f a thrombolytic agent is associated with increased mortal-
ty and composite end points and adds prognostic informa-
ion even in patients with TIMI flow grade 3 (43).
oronary blood flow velocity patterns. In patients with
ubstantial MVO the coronary blood flow velocity pattern is
haracterized by a reduction in systolic antegrade flow, the
ppearance of abnormal retrograde flow in early systole
10 cm/s), and a rapid deceleration of diastolic flow
elocity (600 m/s), which was found to be highly associ-
ted with TIMI flow grade 2 (44,45).
These distinct coronary flow velocity patterns are associ-
ion recovery gradient-echo pulse sequence. (A) Early (2 min after contrast injec-
tral hypoenhanced area corresponding to microvascular obstruction (MVO) in the
RI (10 min after contrast injection) showing hyperenhancement indicating an
MVO). Note that the extent of late MVO is smaller than early MVO, due to con-invers
a cen
ular M
s, lateted with a decreased recovery of LV function over time and
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Microvascular Obstruction April 20, 2010:1649–60eem accurate predictors of long-term cardiac events in
eperfused AMI (46). These altered coronary blood flow
elocity patterns are believed to be related to an increased
icrovascular impedance as a consequence of profound
icrovascular damage and obstruction.
yocardial blush grading. The assessment of TIMI flow
rade and CTFC and the identification of distinct coronary
ow velocity patterns only indirectly reflect the status of the
icrocirculation. Perfusion can also be assessed angio-
raphically with a semi-quantitative description of myocar-
ial contrast density on the final angiogram after reperfu-
ion, described as TIMI myocardial perfusion (TMP) or
yocardial blush grade (47,48). The TMP flow grades are
efined as follows: TMP flow grade 0: failure of dye to enter
he microvasculature; TMP flow grade 1: dye slowly enters
ut fails to exit the microvasculature; TMP flow grade 2:
elayed entry and exit of dye from the microvasculature;
MP flow grade 3: normal entry and exit of dye from the
icrovasculature.
Myocardial perfusion grading also permits risk stratifica-
ion and adds prognostic information even in patients with
IMI flow grade 3. Achievement of both TIMI flow grade
and myocardial blush grade 3 is associated with mortality
nder 1% (49).
Previous studies have shown that 11% of patients who
ad established epicardial patency and TIMI flow grade 3
Figure 4 Sequential Changes in the Microvasculature After Var
At 60 min of ischemia, endothelial cells are swollen with decrease in pinocytotic vesic
emia as large intraluminal protrusions (P), absent or decreased pinocytotic vesicles, m
plugging are observed. With permanent coronary occlusion, intravascular protrusions a
ging with fibrin deposition are seen only after longer duration of ischemia. N  nucleuad a myocardial blush grade of 0/1, again emphasizing that rIMI flow grading is an inaccurate marker of tissue
eperfusion (50). It is believed, however, that myocardial
lush only indirectly reflects microvascular status but pre-
ominantly describes varying degrees of extravasation and
ashout of dye that is caused by a combination of increased
apillary permeability, capillary resistance, and interstitial
dema (51).
The usefulness of angiographic and coronary blood flow
elocity methods to detect MVO is disputable, because they
re often performed immediately after mechanical reperfusion,
time point where microvascular flow is known to be hyper-
mic, and therefore they might not be an accurate reflection of
he final microvascular damage. Experimental studies have
hown that the size of MVO increases depending on the time
fter reperfusion as a result of reperfusion injury (35).
yocardial contrast echocardiography. Myocardial con-
rast echocardiography (MCE) uses small microbubbles
5 m) that possess an intravascular rheology similar to
hat of red blood cells and remain entirely within the
icrovasculature. During constant infusion, a steady state is
chieved after approximately 2 to 3 min. After destruction
ith high energy pulses, the rate of microbubble replenish-
ent is proportionate to blood flow.
Myocardial contrast echocardiography is able to delineate
he area-at-risk for necrosis during acute coronary occlusion
nd has gained tremendous insight into post-ischemic tissue
Periods of Ischemia
pillary damage (endothelial change) continues to occur with longer duration of isch-
ne-bound vesicles (V), and capillary obstruction with red (R) and white (W) blood cell
pronounced; however, membrane-bound vesicles and red and white blood cell plug-
mitochondrium. Reproduced with permission from Virmani et al. (16).ying
les. Ca
embra
re less
s; M eperfusion (52). A persistent contrast defect despite a
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April 20, 2010:1649–60 Microvascular Obstructionatent epicardial artery after reperfusion correlates with
VO (2). Myocardial contrast echocardiography studies
lso made clear that substantial MVO could be observed in
ll patients with TIMI flow grade 2 and in 16% of patients
ith TIMI flow grade 3 (53).
Myocardial contrast echocardiography predicted segmen-
al myocardial recovery with a sensitivity of 88% and a
pecificity of 74% and a positive and negative predictive
alue of 83% and 81%, respectively (54). In addition, MCE
tudies have shown that pericardial effusion, early congestive
eart failure, and adverse arrhythmias occur significantly
ore frequently in patients with MVO (55).
The technique of intracoronary injection of microbubbles
efore and shortly after coronary reflow make it less univer-
ally applicable, and although intravenous methods have
ecome available, several disadvantages to the use of MCE
emain: moderate spatial resolution, operator dependency,
ncomplete LV coverage with suboptimal visualization of
he lateral wall, and semi-quantitative assessment of MVO
54,56).
ardiovascular MRI. Two contrast (gadolinium)-enhanced
ardiovascular MRI techniques are used to detect MVO in
Figure 5 Obstructed Microvessels and
Myocardial Reperfusion Injury
Distal platelet-rich (intramyocardial) embolus (A) when treated with thrombo-
lytic therapy will result in reperfusion injury with (B) contraction band
necrosis (arrowheads) and diffuse neutrophil and red cell infiltration in a
patient with myocardial infarction secondary to epicardial coronary plaque
rupture.MI. The primary technique is first-pass perfusion cardiovas- tular MRI (FPP-CMR) (7,57,58). With this technique, mul-
iple imaging planes are dynamically imaged to track an
ntravenous bolus of contrast into the myocardium. A homog-
nous increase in signal intensity in normal and infarcted
yocardium is observed early after contrast administration,
hereas MVO is seen as an area of reduced signal intensity
hypoenhancement) in the central core of the infarct that
ersists for2 min after contrast administration (early MVO).
The second technique is LGE-CMR (5,59,60). Due to
low washout and local accumulation of contrast 10 to 15
in after contrast injection, the infarcted myocardium
ppears hyperenhanced or “bright” compared with normal
oninfarcted myocardium (61). This hyperenhanced region
losely corresponds to the area of necrosis as measured by
riphenyltetrazolium chloride staining (62). A central hy-
oenhanced region within the hyperenhanced region corre-
ponds to MVO (late MVO).
FPP-CMR was found to be more sensitive for the
etection of MVO compared with LGE-CMR (59). Ex-
erimental studies have demonstrated that the spatial extent
s well as location of early MVO closely correlate with
istopathological analyses (36,63).
LGE-CMR, as compared with FPP-CMR, underesti-
ates the extent of MVO and might miss small regions of
VO due to slow penetration of contrast into the MVO
egion over time (64). FPP-CMR is hampered by incom-
lete LV coverage, low signal-to-noise ratio, and low spatial
esolution interfering with MVO detection. Imaging pro-
ocols that combine early imaging and complete LV cover-
ge might overcome this (65). Not only the timing after
ontrast administration but also the timing of imaging after
MI is important, because only persistent MVO after 1
eek independently predicted adverse LV remodeling, un-
ike MVO that was present at 2 days but disappeared after
week (58).
In contrast to MCE, cardiovascular MRI allows mul-
islice imaging with high tissue contrast and high spatial
esolution, enabling accurate quantification and localiza-
ion of MVO and infarct size relative to the entire LV.
nly one experimental study directly compared MCE
nd FPP-CMR with thioflavin-S staining and found
CE to overestimate and FPP-CMR to underestimate
VO size. This can be explained by the predominantly
ntravascular sojourn of microbubbles, whereas gadolin-
um as a freely diffusible tracer rapidly extravasates into
he interstitium, thereby artificially decreasing the area of
VO (63). In addition, microbubbles are larger than
adolinium molecules and might become temporarily
lugged in microvessels that would allow passage of
adolinium.
Cardiovascular MRI studies have shown that the pres-
nce of MVO significantly increases with infarct transmu-
ality and independently predicts adverse events, including
dverse LV remodeling, congestive heart failure, and death
7,55). In a recent study, the extent of MVO was not found
o be related to the change in LVEF at follow-up, suggest-
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Microvascular Obstruction April 20, 2010:1649–60ng that MVO size might be clinically less important than
ts mere presence (66).
CG. In patients treated with thrombolytic therapy, com-
lete STR (70%) is a highly accurate predictor of infarct-
elated artery (IRA) patency and is associated with lower
ortality (67–69). However, up to 50% of patients with
bsence of complete STR (STR 70%) might still have a
atent IRA and TIMI flow grade 3 (68,70). After successful
rimary PCI and establishment of TIMI flow grade 3, 30%
o 50% of patients have incomplete STR, indicating that
icrocirculatory perfusion might be impaired (71,72). Only
limited number of studies have directly related incomplete
TR to MVO by coronary Doppler flow velocity measure-
ents, cardiovascular MRI, and MCE (66,73,74). The
nterpretation of STR data should be done cautiously,
ecause methodologies, definitions, and time points of
easuring STR differ between studies.
Most studies have used the sum of STR method from
tandard 12-lead ECG, in which ST-segment deviation in
Figure 6 Representative Micrographs of Distal Microembolizati
(A) Low-power (Movat’s pentachrome) view of rupture site (arrow) showing lumina
nonocclusive thrombus composed of necrotic core material. (C) High-power image
ylin and eosin). (D) High-power image of intramural coronary artery atheroembolus
patient who underwent percutaneous coronary intervention for acute myocardial inll leads is summed and compared before and after inter- oention. Single lead STR 50% in the lead with maximum
nitial ST-segment elevation is a simple, universally avail-
ble alternative that predicts TIMI flow grade 3 with 70%
ensitivity and 54% specificity (75). Single lead STR is
omparably accurate in predicting outcome as sum STR
easurements (76). Minimal absolute ST-segment devia-
ion after thrombolytic therapy can also be used to predict
RA patency (77). Because ST-segment elevation and STR
an behave dynamically over time, continuous instead of
erial ECG assessment might provide additional informa-
ion on epicardial patency and quality of myocardial reper-
usion (78).
Other electrocardiographic changes have been described
s signs of successful angiographic reperfusion (TIMI flow
rades 2 or 3). Terminal T-wave inversion was observed in
0% of patients, and a patent coronary artery was associated
ith an increased number of accelerated idioventricular
hythms in small studies (79–81). These markers, however,
nly reflect IRA patency and have not been validated against
Plaque Material From Ruptured Atheroma
and cholesterol clefts. (B) Adjacent distal segment to rupture site demonstrates
nstrating cholesterol clefts (arrows) with superimposed thrombus (Th) (hematox-
ting of cholesterol clefts (arrows) and surrounded by healing myocardium in a
n.on of
l fibrin
demo
consis
farctiother measures of MVO.
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espite major advances in the understanding of the under-
ying pathophysiology of MVO, many different mechanical
nd pharmacologic therapeutic approaches to prevent or
ttenuate MVO have revealed very different and, in part,
ontradictory results. Interventions that were effective in the
xperimental setting did not show significant effects clini-
ally, and vice versa.
The use of a microcirculatory protection device effectively
etrieved embolic debris during PCI in AMI but failed to
mprove microvascular flow, reduce infarct size, or result in
nhanced event-free survival (32). Although the aspiration
f thrombus significantly improved reperfusion compared
ith conventional PCI, a substantial number of patients still
Figure 7 Different Regions of Microvascular Flow After Reperfu
Schematic short-axis presentation showing the different regions of microvascular fl
linical Methods to Detect MVOTable 1 Clinical Methods to Detect MVO
Technique
Invasive
Coronary angiography
TIMI flow grade
Corrected TIMI frame count
Coronary blood flow patterns
Systolic retrograde flow
Diastolic flow velocity deceleration
Myocardial blush grade
TMP grade
Noninvasive
Myocardial contrast echocardiography Contras
Cardiovascular magnetic resonance imaging
Early contrast enhancement Central
2 m
Late contrast enhancement Central
usua
Electrocardiography
ST-segment resolution (60–90 min after reperfusion)
ST-segment deviation (90 min after reperfusion) 1 mm foPP  first pass perfusion; MI myocardial infarction; MVO  microvascular obstruction; TIMI  Thrombxperienced low myocardial blush grades and incomplete
TR (82). Likewise, intra-aortic balloon counterpulsation
ignificantly reduced MVO experimentally, but a recent
eta-analysis of clinical studies using intra-aortic balloon
ounterpulsation in the setting of ST-segment elevation
yocardial infarction suggested that this is not associated
ith a change in LVEF and increased survival at follow-up
83,84).
A range of pharmacologic adjunctive measures of reper-
usion have been evaluated. Glycoprotein IIb/IIIa inhibition
ignificantly improved microvascular flow and reduced in-
arct size in a dog model of coronary occlusion/reperfusion
nd significantly increased the rate of complete STR,
oronary artery patency, and CTFC in clinical trials
reperfused acute myocardial infarction.
Generally Accepted as MVO Ref. #
2 (42)
40 (49)
10 cm/s (44,45)
600 m/s (44,45)
1 (47,50)
t within area at risk despite angiographic reperfusion (2,53)
hancement within the infarcted area that persists
er contrast injection during FPP (early MVO)
(7,57,58)
hancement within the area of hyperenhancement,
15 min after contrast injection (late MVO)
(5,59,60)
30% (67,70,74)
ior MI, 2 mm for anterior MI (77)sion
ow int defec
hypoen
in aft
hypoen
lly 10–
r inferolysis In Myocardial Infarction; TMP  TIMI myocardial perfusion.
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Microvascular Obstruction April 20, 2010:1649–6085–88). Possibly by reversing microvascular spasm, the
dministration of intracoronary verapamil after PCI de-
reased no-reflow zones leading to a better functional
utcome in first AMI patients (89). The extent of MVO is
roportional to the number of polymorphonuclear leuko-
ytes present in the infarcted area. The inhibition of
omplement pathways decreased polymorphonuclear leuko-
yte free radical generation and enhanced the recovery of
oronary flow in an isolated rat heart model (90,91).
Circulating levels of endothelin, a potent and long-acting
asoconstrictor, are low in normal individuals but increased
uring ischemia, with a further increase during reperfusion
16). Endothelin-mediated vasoconstriction, neutrophil
lugging, and microvascular permeability play a role in the
athogenesis of MVO. The significant reduction of MVO
nd infarct size in a canine model after the administration of
n endothelin A-receptor antagonist after 90 min of coro-
ary occlusion supports this concept (92).
Selective administration of intracoronary adenosine at-
enuated functional and structural abnormalities of the
icrovasculature, leading to improved regional ventricu-
ar function as compared with placebo in a canine model
93). In the clinical setting, however, although infarct
ize was reduced, a 3-h infusion of adenosine in reper-
used ST-segment elevation myocardial infarction pa-
ients failed to show an improved outcome in the AMISTAD
I (Acute Myocardial Infarction STudy of ADenosine)
rial (94).
These discrepant results underscore the complex underlying
echanisms implicated in the pathophysiology of MVO and
uggest that successful therapy should be multitargeted.
onclusions
emporary coronary occlusion followed by reperfusion results
n microvascular damage—with endothelial swelling, neutro-
hil activation, and entrapment—leading to reperfusion-
nduced myocardial damage. Microvascular flow after reperfu-
ion is spatially and temporally complex. Regions of hyperemia,
mpaired vasodilatory flow reserve, and very low flow coexist.
he magnitude and spatial extent of these perfusion patterns
ary over time as a result of reperfusion injury. Microvascular
bstruction is independently associated with adverse LV re-
odeling and prognosis. Therefore, its detection is crucial.
everal techniques (coronary angiography, MCE, cardiovascu-
ar MRI, ECG) measuring slightly different biological and
unctional parameters are used clinically and experimentally for
he evaluation of MVO (Table 1). Currently, there is no consen-
us on how and when MVO should be evaluated after AMI.
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